Two hallmarks of measles virus (MV) infection are the ability of the virus to cause immunosuppression and the resultant enhanced susceptibility of the infected host to microbial insults. We investigated the effect of MV infection on the ability of dendritic cells (DCs) to induce IL-12 via toll-like receptor (TLR) signaling. When infected with MV, transgenic mice which expressed human SLAM receptor on their DCs were defective in the selective synthesis of IL-12 in DCs in response to stimulation of TLR4 signaling, but not to engagements of TLR2, 3, 7 or 9. MV suppressed TLR4-mediated IL-12 induction in DCs even in the presence of co-stimulation with another ligand for TLR2, 3, 7, or 9. While MV V and C proteins were not responsible for IL-12 inhibition, interaction of MV hemagglutinin with human SLAM facilitated the suppression. These results suggest that MV, by altering DC function, renders them unresponsive to secondary pathogens via TLR4.
Introduction
Immunosuppression associated with opportunistic infections is responsible for most of the current 500,000 measlesrelated deaths annually (CDC, 2005; Griffin, 2001) . Measles virus (MV) interferes with the function of dendritic cells (DCs) by enhancing their apoptosis (Fugier-Vivier et al., 1997; ServetDelprat et al., 2000a) , upregulating expression of TNF-related apoptosis-inducing ligand (TRAIL) (Vidalain et al., 2000) , altering CD40 ligand-dependent differentiation (Servet-Delprat et al., 2000b) , inhibiting DC development via STAT2 signaling (Hahm et al., 2005) , and suppressing DC-stimulated proliferation of T lymphocytes (Dubois et al., 2001; Grosjean et al., 1997; Klagge et al., 2000; Schnorr et al., 1997) . MV was reported to activate TLR2 signaling (Bieback et al., 2002) and suppress TLR7 and TLR9-stimulated production of type I IFNs from plasmacytoid DCs (Schlender et al., 2005) . MV infection skews host immune response towards Th2 phenotype (Griffin and Ward, 1993) . This suppression of Th1-mediated cellular immune responses was thought to result from the inhibition of IL-12 synthesis (Karp et al., 1996) . Indeed, suppression of IL-12 was reported in MV-infected children (Atabani et al., 2001) , in rhesus macaques during measles (Polack et al., 2002) , in MVinfected transgenic (tg) mice expressing CD46 receptor (Marie et al., 2001) , and in DCs generated from human PBMC when infected by MV (Fugier-Vivier et al., 1997; Servet-Delprat et al., 2000b) . CD46 and MV nucleoprotein were suggested to play a role in the inhibition of IL-12 production from monocytes/DCs (Karp et al., 1996; Marie et al., 2001) .
Two cellular receptors CD46 and signaling lymphocyte activation molecule (SLAM) on human cells were reported to interact with MV hemagglutinin (HA) permitting viral entry into cells (Dorig et al., 1993; Manchester et al., 1994; Naniche et al., 1993; Tatsuo et al., 2000) . MV is a human but not a rodent pathogen. Studies that engineer mice to express the MV receptors have greatly aided in dissecting the pathogenesis of this virus. Generation of tg mice expressing human CD46 (Blixenkrone-Moller et al., 1998; Horvat et al., 1996; Mrkic et al., 1998; Oldstone et al., 1999; Rall et al., 1997) or SLAM (Hahm et al., 2003 (Hahm et al., , 2004 Sellin et al., 2006; Shingai et al., 2005; Welstead et al., 2005) has been reported.
Here, we utilize tg mice that express human (h) SLAM on their DCs (Hahm et al., 2004) . Investigation of responses of MV-infected DCs to various TLR stimulations revealed that MV significantly inhibited production of IL-12 but not of IL-6 and TNF-α from DCs in response to TLR4 stimulation. This inhibition of IL-12 was selective for TLR4 signaling as it did not occur in the presence of signaling by TLR2, TLR3, TLR7, or TLR9. The interaction of MV HA with hSLAM receptor contributed to the suppression of IL-12.
Results and discussion

Differential responses of measles virus-infected DCs to TLR activations in producing cytokines
We previously engineered mice to express human (h) SLAM on DCs (Hahm et al., 2004) . DCs from such mice were susceptible to MV. To examine whether MV affects DC capability of producing cytokines in response to various TLR activations, bone marrow (BM)-derived DCs from tg mice were infected with MV, treated with TLR ligand (L), after which their production of cytokines was analyzed. In our in vitro MV infection analysis, approximately 30% of CD11c+ DCs were infected with MV by FACS. MV-infected DCs were significantly suppressed in synthesizing IL-12p70/p40 when responding to TLR4 stimulation with pure LPS by FACS (37% of IL-12-producing cells from control cells vs. 6% from MV-infected DCs measured for 5 h at 2 h post LPS treatment; Fig. 1A ) or secreted heterodimeric form of IL-12p70 by ELISA analysis (Fig. S1 ). The degree in IL-12 suppression was dependent on viral infectivity of DCs (data not shown). However, IL-12 inhibition was hardly observed when MV-infected DCs were treated with peptidoglycan (PGN, TLR2L), poly(I:C) (TLR3L) (data shown in Fig. 2E ), CpG DNA (TLR9L) or loxoribine (TLR7L) (Fig. 1A) . TLR4-mediated IL-12 inhibition was observed 24 h after TLR4 stimulation with the treatment of varying concentrations of LPS (1 to 1000 ng/ml) in MV-infected DCs (Fig. 1B) . MV infection induced DCs to produce more IL-12 (Fig. 1A) and TNF-α (Fig.  1E ) in response to loxoribine treatment compared to mockinfected DCs. These results indicated that MV infection sensitized DCs to TLR7 signaling. Two cytokines, Flt3-L and GM-CSF are critical for DC development, DC survival, and different DC subset generation (Daro et al., 2002) . MV suppressed IL-12 production after TLR4 engagement in DCs generated by either Flt3-L or GM-CSF-supplemented DC culture systems (Fig. 1C) .
DCs from spleens of tg mice infected with MV in vivo (approximately 10% of DCs were infected with MV) did not efficiently respond to TLR4 activation to produce IL-12 (Fig. 1D ). In contrast, such DCs retained potential to yield IL-12 (Fig. 1D) or TNF-α (data not shown) when they were activated by CpG DNA, a TLR9L, results consistent with in vitro MV infection (Fig. 1A) . MV targets TLR4 signaling to selectively suppress IL-12, as TLR4-mediated production of other inflammatory cytokines such as TNF-α and IL-6 was not diminished in MV-infected DCs ( Fig. 1E and F) . Furthermore, TLR4/MD2 complex expression on the surface of DCs hardly changed in LPS-treated DCs by MV infection (Fig. S2) . Collectively, the data indicates that MV specifically inhibits IL-12 production in response to TLR4 activation. Molecular mechanisms (Agrawal et al., 2003; Aste-Amezaga et al., 1998; Reis e Sousa, 2004; Takeda and Akira, 2004) of MV-induced IL-12 inhibition upon TLR4 activation remain to be uncovered.
MV suppresses TLR4-mediated IL-12 production even in the presence of TLR2, TLR3, TLR7, or TLR9 stimulation Since Gram-negative bacteria contain potential motifs of both TLR4L (LPS) and TLR9L (CpG DNA), two TLR signaling pathways could be stimulated on DCs simultaneously by a pathogenic invasion. When mock-infected DCs were stimulated with both LPS and CpG DNA at the same time, they enhanced the production of IL-12 either additively or synergistically compared to the production by either treatment alone also confirming the report of Napolitani et al. (2005) . Interestingly, although MV-infected DCs responded to CpG treatment alone (28% of IL-12 producing cells in Fig. 2A ) as seen for mockinfected DCs, they were suppressed substantially in yielding IL-12 in response to co-treatment of both LPS and CpG (7% of IL-12+ cells). Addition of various amount of CpG DNA (2 ng/ml to 2 μg/ml; Fig. 2B , data not shown) could not restore IL-12 production from MV-infected DCs in the presence of LPS (0.1 ng/ml to 1000 ng/ml). Furthermore, pre-treatment of CpG DNA onto MV-infected DCs 1 h before LPS treatment failed to induce significant increase in IL-12 synthesis additively, which was observed in mock-infected DCs (Fig. 2C) . As MV replication makes DCs respond to the engagement of TLR7 by loxoribine treatment to enhance the production of inflammatory cytokines, we added both LPS and loxoribine onto MV-infected DCs and analyzed IL-12 synthesis compared to mock-infected DCs. Whereas IL-12 was increased in MV-infected DCs in response to TLR7 activation compared to mock-infected DCs, IL-12 expression was significantly altered when the cells were stimulated with ligands for both TLR7 and TLR4 (Fig. 2D) . Similarly, suppression of IL-12 was observed in the combinations of LPS plus either poly(I:C), (TLR3L) or PGN (TLR2L) (Fig. 2E) . Treatment of loxoribine, poly(I:C), or PGN did not suppress CpG-induced IL-12 production in MV-infected DCs.
MV HA interaction with SLAM receptor contributes to the suppression of IL-12 MV V and C proteins have been reported to suppress host immune responses including inhibition of interferon signaling pathways (Palosaari et al., 2003; Patterson et al., 2000; Shaffer et al., 2003; Takeuchi et al., 2003) . To determine the role, if any, of MV proteins V or C in the TLR4/IL-12 targeting by MV, we used functional recombinant MV defective in V [MV-V(−)] or C gene [MV-C(−)] generated by reverse genetics (Patterson et al., 2000) . These mutant viruses lacking either V or C genes of measles had the same potential to suppress TLR4-mediated IL-12 production as did wild type MV (Fig. 3A) . However, these specific defective viruses did not inhibit TLR9-mediated IL-12 synthesis similar to the effect seen with wild-type MV (data not shown). The results indicate that MV V and C proteins are not responsible for IL-12 suppression mediated via TLR4 signaling.
Human SLAM is a receptor that binds to MV HA (Tatsuo et al., 2000) . DCs from tg mice expressing solely hSLAM receptor, but not the other MV receptor CD46, provided the opportunity to determine a possible role of MV HA-hSLAM interaction in IL-12 suppression observed in DCs. UVinactivated MV (UV-MV) barely affected IL-12 production from hSLAM(−) DCs of non-tg wt mice. In contrast, UV-MV suppressed IL-12 expression from hSLAM(+) DCs in a viral dose-dependent manner (Fig. 3B) , although the inhibition was not as strong as seen with replication competent MV (Fig. 3A) . The data indicates that MV HA binding to hSLAM facilitates TLR4-mediated IL-12 suppression in MV infection. As IL-12 suppression was observed in both populations of MV-uninfected DCs [MV(−) DCs] and MV(+) DCs when they were treated with MV (Fig. S3) , it is possible that MV HA expressed on MV(+) cells interacts with hSLAM receptor on MV(−) cells to cause an inhibition of TLR4-mediated IL-12 synthesis in uninfected cells. It remains to be investigated if or how MV affects SLAM signaling involved in TLR4-mediated cytokine production on DCs (Wang et al., 2004) .
In summary, we show for the first time that MV infection of DCs via SLAM receptor suppresses TLR4-mediated IL-12 induction. This TLR4/IL-12 suppression occurs even in the presence of the activation of TLR2, TLR3, TLR7, or TLR9. MV does not interfere with production of TNF-α and IL-6, indicating that this virus' ability to target IL-12 in the engagement of TLR4 is a specific event. IL-12 is a key cytokine inducing cellular immune responses to protect host from the harm caused by pathogenic infections (Trinchieri, 2003) . Our data indicates that MV has devised a clever way to suppress IL-12-mediated 
Materials and methods
Mice
Mice were maintained in the closed breeding colony of The Scripps Research Institute. The origin, genotyping, and use of CD11c-hSLAM tg mice has been reported (Hahm et al., 2004) . 
Cells
BM cells were isolated and cultured to generate DCs as described (Hahm et al., 2005) . BM cells obtained were cultured with a supplementation of either 200 U/ml rmGM-CSF (Peprotech Inc., Rocky Hill, NJ) or 100 ng/ml Flt3-L (Amgen Inc., Thousand Oaks, CA). After 10 days of culture, nonadherent cells were pooled by gentle pipetting and then used as a source of BM-derived DCs. DCs were obtained from spleens of tg mice after digestion with collagenase D (1 mg/ml, type II; Sigma Aldrich, St. Louis, MO) at 37°C for 15 min. To disrupt T cell-DC complexes, 0.01 M of EDTA was added and incubation continued for 5 min as described (Hahm et al., 2005) .
Analysis of MV infection
Wild-type MV, JW strain, were passaged on B95-8 cells (fewer than 10 times) to sufficiently enhance viral titers for experimental study. MV-C(−) and MV-V(−) were passaged and titered on Vero cells as described (Patterson et al., 2000) and were originally a gift from Martin A. Billeter (University of Zurich). MV was inactivated by UV-exposure for 30 min with a 254-nm UV lamp and loss of infectivity measured by TCID 50 assay. For MV-binding to DCs in vitro, BM-derived DCs were incubated on ice with either MV-free media as a negative control (mock infection) or MV at 1.0-2.0 multiplicity of infection (MOI) for 2 h. After washing, cells were recultured in GM-CSF-or Flt3-L-supplemented media. For in vivo MV infection, five 8-to 12-week-old tg mice were injected intravenously (i.v.) with MV-JW at a dose of 2 × 10 7 TCID 50 in a volume of 250 μl. Mice were sacrificed 2 days after inoculation and splenocytes harvested as above. For a negative control, MV-free B95-8 cell supernatants were prepared identically to JW virus stock and used for mock in vivo infection analysis.
Stimulation of TLRs
DCs were infected with MV for 1 to 2 days and then treated with ligands for TLRs. Peptidoglycan (Sigma Aldrich, St. Louis, MO), synthetic analog of double stranded RNA poly (I:C) (InvivoGen, San Diego, CA), lipopolysaccharide (Alexis Biochemicals, San Diego, CA), guanosine analog loxoribine (InvivoGen), and CpG DNA (ODN 1826) (InvivoGen) were used to stimulate TLR2, TLR3, TLR4, TLR7, and TLR9 on DCs, respectively. The content of LPS in virus stock or control stock was analyzed in a bioassay (Hoebe et al., 2003) and shown to be less than 0.1 ng/ml, which was a minimal limit in the assay.
ELISA analysis
BM-derived DCs (10 5 cells/well) were infected with mock or MV for 24 h. Cell-free culture supernatants were harvested at 24 h after treatment of LPS (10 or 100 ng/ml). Secreted heterodimer of IL-12p70, which is composed of p35 and p40 (contemporary nomenclature for p40 subunit is IL-12/23p40) was measured by a specific ELISA kit (e-Bioscience, San Diego, CA).
Flow cytometric analysis
Cells were incubated with various fluorochrome-conjugated antibodies for 20 min on ice in PBS containing 1% FBS and 0.1% sodium azide. Antibodies for this study included specific for murine CD11c, CD11b, and TLR4/MD2 complex antibodies (BD PharMingen or e-Bioscience, San Diego, CA). For the detection of surface MV proteins, cells were incubated with a human polyclonal serum to MV for 20 min, washed three times, and then stained with PE-conjugated donkey antihuman IgG antibody (Jackson Immunoresearch Laboratories) (Hahm et al., 2004) . For intracellular staining of cytokines, cells were treated with 4 μg/ml Brefeldin A (Sigma Aldrich) for the last 5 h of TLR stimulation, fixed and permeabilized with 4% paraformaldehyde and 0.1% saponin in HBSS, and then stained with antibodies against IL-12 p40/p70, IL-6, or TNF-α (BD PharMingen or e-Bioscience) in permeabilization buffer (0.1% saponin and 1% FBS in PBS). Antibody against IL-12(p40/p70) (BD PharMingen) reacts with both free and complexed (homodimer p80 and heterodimer p70) forms of the p40 subunit (IL-12/23p40) of mouse IL-12 detecting both p40 subunit (IL-12/23p40) and p70 heterodimer. Fluorescent cells were acquired with a FACSCalibur™ flow cytometer (Becton Dickinson, San Jose, CA) then analyzed with FlowJo software. 
